ACTA SCIENTIFIC MICROBIOLOGY (ISSN: 2581-3226)

Volume 3 Issue 11 November 2020

Review Article

A Review of Anti-Inflammatory Drugs Use in the Treatment of People Infected by Coronavirus Disease 2019 (COVID-19)

Anirban Adhikary[1]*, Kakoli Halder[1], Debmalya Ghosh[1], Snehansu Biswas[2], Indranil Chatterjee[2] and Suman Kumar Nath[2]

[1]B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India

[2]Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India

***Corresponding Author:** Anirban Adhikary, B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.

Received: August 24, 2020

Published: October 15, 2020

© All rights are reserved by **Anirban Adhikary., *et al.***

Abstract

The pandemic flare-up of coronavirus disease 2019 (COVID-19) is quickly spreading everywhere throughout the world. Reports from China indicated that about 20% of patients created severe disease, bringing about a casualty of 4%. In the previous two months, we clinical immunologists took an interest in multi-rounds of MDT (multidiscipline group) conversation on the counter aggravation the executives of basic COVID-19 patients, with our partners dispatched from Chinese driving PUMC Hospital to Wuhan to concede and treat the most serious patients. Here, from the point of view of clinical immunologists, we will examine the clinical and immunological attributes of severe patients, and sum up the current proof and offer our involvement with hostile to anti-inflammation treatment, including glucocorticoids, IL-6 adversary, JAK inhibitors and chloroquine/hydroxychloroquine, of patients with extreme COVID-19 that may have an impeded safe framework.

Keywords: Coronavirus Disease 2019 (COVID-19); Cytokine Storm; Anti-inflammation Treatment

Introduction

Since the abrupt flare-up of coronavirus disease 2019 (COVID-19) in Wuhan City, China brought about by extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2), in only two additional months, the pestilence has quickly spread everywhere throughout the world. On March 11, 2020, the World Health Organization (WHO) pronounced the COVID-19 episode a pandemic. Till March 22, all around, roughly 303,000 affirmed cases, remembering in excess of 12,900 passing for around 150 nations. Information from China have demonstrated that about 20% of patients created extreme malady, more seasoned grown-ups, especially those with genuine basic wellbeing conditions, are at higher danger of death than more youthful ones. A minority of patients gave respiratory disappointment, septic stun and multiorgan brokenness bringing about a casualty of 4%. In the previous multi month, we participated in a serial of remote teleconsultation, talking about a few basic COVID-19 patients in escalated the point of view of clinical immunologist and rheumatologists, we might want to examine and share our involvement with the treatment of severe COVID-19.

Several important features in critical COVID-19 patients

From the perspective of rheumatologists, aside from respiratory disappointment, the basic COVID-19 patients have basic highlights: 1) unexpected decay of sickness around one to about fourteen days after beginning; 2) much lower level of lymphocytes, particularly natural killer (NK) cells in fringe blood; 3) incredibly high incendiary boundaries, including C reactive protein (CRP) and supportive of fiery cytokines (IL-6, TNFα, IL-8., *et al.*); 4) crushed invulnerable framework uncovered by decay of spleen and lymph hubs, alongside diminished lymphocytes in lymphoid organs; 5) most of penetrated safe cells in lung injury are monocytes and macrophages, yet insignificant lymphocytes invasion; 6) mimicry of vasculitis,

hypercoagulability and various organs harm. In view of the above qualities of COVID-19, we talk about the accompanying focuses as far as treatment.

Inflammatory cytokine storm was very common in patients with severe COVID-19

Cytokine storm (CS) alludes to over the top and uncontrolled arrival of supportive of incendiary cytokines. Cytokine storm disorder can be brought about by an assortment of ailments, including irresistible maladies, rheumatic ailments and tumor immunotherapy. Clinically, it ordinarily presents as fundamental irritation, various organ disappointment and high fiery boundaries. In irresistible maladies, CS for the most part begins from the central tainted region, spreading everywhere throughout the body through course. In coronavirus pneumonia, for example, serious intense respiratory condition (SARS) and Middle East respiratory disorder (MERS), joined by quick infection replication, countless fiery cell invasion and CS prompted intense lung injury, intense respiratory trouble disorder (ARDS) and demise [1,2]. Amassing proof uncovered that a piece of extreme COVID-19 patients have a raised cytokine profile looking like CS in SARS and MERS. Huang., *et al*. announced the degree of provocative components in patients with COVID-19. They estimated cytokine levels in 41 inpatients (counting 13 ICU patients and 28 non ICU patients), IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast development factor (FGF), granulocyte macrophage state invigorating variable (GM-CSF), IFNγ, granulocyte colony animating component (G-CSF), interferon-γ-inducible protein (IP10), monocyte chemoattractant protein (MCP1), macrophage provocative protein 1 alpha (MIP1A), platelet determined development factor (PDGF), tumor corruption factor (TNFα), vascular endothelial development factor (VEGF) were expanded, among which IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNFα were higher in extreme patients [3,4]. Strikingly, there was not articulate contrast of serum IL-6 level been the ICU and non ICU patients. Notwithstanding, in another review, multicentre companion study, a similar report bunch revealed a fundamentally rise of IL-6 level in non-endurance gathering of patients with COVID-19, as contrasted and that of the stabilities [5]. A few different reports additionally affirmed the rise of IL-6 in basically sick patients with COVID-19 [6-8].

In serious COVID-19, in spite of the fact that patients have lymphocytopenia, the lymphocytes were initiated. One investigation dissected the lymphocyte subsets and cytokines in 123 patients, all patients had lymphocytopenia, the level of CD8 + T cell decrease were 28.43% and 61.9% in mellow and serious gathering separately, and the NK cell decrease were 34.31% and 47.62% respectively, in gentle and extreme gatherings. Likewise, serum IL-6 levels in extreme gathering were altogether higher than that in gentle group [9]. What's more, the outflow of HLA-DR in CD4 + and CD8 + cells was expanded, CD4 + CCR4 + CCR6 + Th17 cells likewise expanded, and the cytotoxic particles, for example, perforin and granolysin were exceptionally communicated in CD8 + T cells [10].

Steady with others, the greater part of serious COVID-19 patients in our ICU ward had constant extremely elevated level of erythematosus sedimentation rate (ESR), CRP, and significant level of IL-6,TNFα, IL-1β, IL-8, IL2R, and so forth., and were related with ARDS, hypercoagulation and scattered intravascular coagulation (DIC), showed as apoplexy, thrombocytopenia, gangrene of furthest points. It is conceivable that CS fuels lung harm just as prompts other fetal confusions. Siddiqu and Mehra [11] proposed a 3-phase order model, perceiving that COVID-19 sickness showed three evaluations of expanding seriousness which compared with unmistakable clinical discoveries, reaction to treatment and clinical result. A little extent of COVID-19 patients would travel into the third and most serious phase of sickness, which showed as an extrapulmonary foundational hyperinflammation condition. In this stage, markers of fundamental irritation had all the earmarks of being incredibly raised. In this way, how to obstruct the CS and when to start hostile to aggravation treatment is basic for decreasing passing pace of COVID-19.

The immune system was impaired in critical COVID-19 patients

Lymphocytopenia is one of the most noticeable markers of COVID-19, it's additionally one of the demonstrative measures for COVID-19 in China [12]. Both T cells and NK cells in patients with COVID-19 were diminished. The level of decrease was even lower in serious cases the last had higher leukocytes checks and neutrophil-lymphocyte-proportion (NLR) too. In some basic sick patients, NK cells were amazingly low, or even imperceptible. What's more, memory partner T cells and administrative T cells were clearly diminished in serious cases [13].

All the more strikingly, the post-mortem examination discoveries uncovered that the optional lymphoid tissues had been demolished in COVID-19 patients, which is irregular from different CS related ailments. Spleen decay was seen in completely detailed cases with diminished quantities of lymphocyte, and critical cell

degeneration, central hemorrhagic corruption, macrophage multiplication and macrophage phagocytosis were found in spleen. Correspondingly, lymph hub decay and the quantity of lymph hubs diminished, joined by rot. Immunohistochemical recoloring indicated that CD4+ T cells and CD8+ T cells were diminished in spleen and lymph hubs [13]. Moreover, in the lung with trademark diffused alveolar harm (DAD), the major penetrated cells were monocytes and macrophages, moderate multinucleated mammoth cells, yet not many lymphocytes. A large portion of the invading lymphocytes were CD4-positive T cells. Critically, infection incorporation bodies can even now be identified in type II alveolar epithelia and macrophages, in spite of that the PCR test was negative in blood or throat swabs [10,12,14]. This finding is predictable with the attributes of the supposed "essential cytokine" storm actuated by viral contamination which were fundamentally delivered by alveolar macrophages, epithelial cells and endothelial cells, instead of those saw in "auxiliary cytokine" storm initiated by various subsets of enacted T lymphocytes in late phase of viral disease or an intricacy of T cell-drawing in treatments [15,16].

There are two potential explanations behind the annihilation of the safe framework in patients with COVID-19, lymphocytes legitimately attacked by infection or by implication harmed by CS. As we realize that 2019-nCoV taints target cells through angiotensin changing over chemical 2 (ACE2), while there was no ACE2 articulation on lymphocytes, we estimate that lymphocytes were presumably wrecked by CS.

Mimicry of vasculitis and thrombosis are prominent features in severe COVID-19 patients

Another noticeable clinical indication in serious COVID-19 patients is endothelium harm. Mimicry of vasculitis could be seen in extreme COVID-19 patients. Clinically, numerous basic sick patients have vasculitis-like appearances, or even gangrene at their limits; Pathology assessment uncovered the veins of alveolar septum were clogged and edematous, with unassuming penetration of monocytes and lymphocytes inside and around veins. Little vessels demonstrated hyperplasia, vessel divider thickening, lumen stenosis, impediment and central discharge. Hyaline thrombi of smaller scale vessels were found in an extent of extreme cases [10,13,14]. Intriguingly, a few patients were tried positive with high titer antiphospholipid antibodies, including anticardiolipin antibodies and hostile to β2 glycoprotein antibodies, and were related with serious apoplexy (unpublished information). The fundamental instrument of vascular harm might be because of the immediate injury of endothelial cells by infection, prompting DIC, hostile to phospholipid disorder (APS) and mimicry of vasculitis. The neurotic immune system reactions associated with the counter infection resistance are worth to be accentuated.

Current knowledge of anti-inflammation treatment in COVID-19 patients

Almost certainly antiviral and steady medicines are significant in the treatment of patients with COVID-19. As CS is moderately regular in extreme case and frequently prompts the fuel, hostile to aggravation treatment may help in forestalling further injury. As we probably am aware, there are an assortment of calming meds, including non-steroidal mitigating drugs, glucocorticoids, chloroquine/hydroxychloroquine, immunosuppressants, incendiary cytokines rivals, (for example, IL - 6R monoclonal antibodies, TNF inhibitors, IL-1 enemies, janus kinase inhibitor (JAK) inhibitors., *et al*. Siddiqu and Mehra recommended that custom fitted treatment in stage III depends on the utilization of immunomodulatory operators to decrease foundational aggravation before it overwhelmingly results in multi-organ brokenness. In this stage, utilization of corticosteroids might be defended working together with the utilization of cytokine inhibitors, for example, tocilizumab (IL-6 inhibitor) or anakinra (IL-1 receptor enemy). Intravenous safe globulin (IVIG) may likewise assume a job in balancing a resistant framework that is in a hyperinflammatory state. By and large, the anticipation and recuperation from this basic phase of ailment is poor, and brief acknowledgment and utilization of such treatment may have the best yield [11,17].

Be that as it may, there is issue of calming treatment, adjusting the hazard and advantage proportion is a basic issue. Would it be a good idea for us to apply hostile to aggravation treatment to COVID-19 patients? Which patient would it be a good idea for us to treat with hostile to aggravation routine, and when to begin? What is the treatment span? Which prescription is the most ideal decision? All the above inquiries are as yet under serious discussion and don't arrive at an accord. The principle concern is that calming drugs, for example, corticosteroid, may postpone the disposal of infection and increment the danger of auxiliary disease, particularly in those with debilitated insusceptible system. Secondly, organic operators focusing on supportive of provocative cytokines can just repress explicit fiery factor, and in this manner may not be compelling in controlling the CS in COVID-19 in which different cytokines possibly critical. Thirdly, some enemy of irritation drug, for example, JAK inhibitors additionally square INF-a creation, which is signifi-

cant in battling infection, and hypothetically may not be appropriate for the treatment of provocative CS brought about by infection as COVID-19. At last, the time window of mitigating treatment is significant. As indicated by reports and our perception, serious patients typically experienced sudden disintegration in 1 fourteen days after beginning, and brief commencement of the mitigating treatment at this amazingly brief timeframe window is probably going to accomplish an ideal treatment reaction.

Glucocorticoids

Various clinical investigations have announced the viability of glucocorticoids in the treatment of coronavirus pneumonia, (for example, SARS and MERS) or flu pneumonia, yet no agreement has been reached. During the SARS scourge in 2003, glucocorticoid was the primary drug of immunomodulatory treatment. Convenient utilization of glucocorticoid could improve the early fever, advance the ingestion of pneumonia and get better oxygenation. Be that as it may, a few investigations didn't show useful impacts with glucocorticoid, or even unfriendly responses or deferred infection freedom, prompting crumbling of the illness [18-21]. As indicated by worldwide rules for the board of sepsis and septic stun, if glucocorticoid is to be utilized, little measurement and transient application ought to be applied uniquely for patients in whom sufficient liquids and vasopressor treatment don't reestablish hemodynamic steadiness [22]. At present, fundamental glucocorticoids organization was experimentally utilized for extreme intricacies so as to smother CS appearances in patients with COVID-19, for example, ARDS, intense heart wounds, intense kidney confusion and patients with higher D-dimer levels [3,23,24]. However, there is no proof from randomized clinical preliminaries to help glucocorticoids treatment for COVID-19. Chen., *et al*. revealed 19 (19%) patients were treated with glucocorticoids for 3 - 15 days (middle 5 (3 - 7)) and methylprednisolone (1 - 2 mg/kg every day) are suggested for patients with ARDS, for as short a term of treatment as conceivable [25]. Nonetheless, a few confirmations demonstrate that the advantage of the utilization of glucocorticoids is likely exceeded by unfriendly impact. Wang., *et al*. detailed 44.9% patients of COVID-19 were given glucocorticoid treatment, with no viable results watched [26]. Russell., *et al*. revealed clinical proof didn't bolster corticosteroid treatment for COVID-19 lung injury [27]. Because of the absence of confirmations, the interval rule of WHO doesn't bolster the utilization of fundamental corticosteroids for the treatment of viral pneumonia and ARDS for suspected COVID-19 cases in 22 February 2020 [28]. Along these lines, viability and related antagonistic impacts of glucocorticoids in COVID-19 need additionally explained.

Tocilizumab treatment of CS

Tocilizumab (TCZ) is a recombinant human IL-6 monoclonal neutralizer, which explicitly ties to solvent and layer bound IL-6 receptors (IL-6R), in this way blocking IL-6 flagging and its intervened provocative reaction. TCZ has been broadly utilized in rheumatic maladies, for example, rheumatoid joint inflammation. On August 30, 2017, TCZ was affirmed in the United States for serious dangerous cytokine discharge condition brought about by fanciful antigen receptor T-cell (CART) immunotherapy. Wei Haiming., *et al*. led a review study watching the adequacy of tocilizumab in treating serious or basic COVID-19 patients (to be published). Alongside the essential enemy of infection treatment, TCZ was applied to 20 patients 400 mg once intravenously. Inside a couple of days, the fever came back to ordinary and different indications improved astoundingly. 75.0% had improved oxygenation. The mistiness lung injury on CT filters assimilated in 90.5% patients. Moreover, the level of fringe lymphocytes came back to ordinary in 52.6% patients. Their information recommends TCZ may be a powerful treatment in serious patients of COVID-19.

Till now, a few clinical preliminaries have been enlisted on security and viability of tocilizumab in the treatment of serious COVID-19 pneumonia in grown-up inpatients, including a multicenter, randomized controlled preliminary for the adequacy and wellbeing of tocilizumab in the treatment of novel coronary pneumonia (NCP) (ChiCTR2000029765), a solitary arm open multicenter concentrate on tocilizumab (ChiCTR2000030796), and mix of tocilizumab and different medications (ChiCTR2000030442 and ChiCTR2000030894).

JAK inhibitors

The receptors of novel coronavirus pneumonia (2019-nCoV), may be ACE2, which is a cell-surface protein generally existed on cells in the heart, kidney, veins, particularly alveolar epithelial cells. 2019-nCoV could attack and enter cells through endocytosis. One of the known controllers of endocytosis is the AP2-related protein kinase 1 (AAK1). AAK1 inhibitors can interfere with the entry of the infection into cells and can be useful in forestalling infection contaminations. Baricitinib, a JAK inhibitor just as an AAK1 inhibitor, was recommended a potential contender for treatment of COVID-19, thinking about its relative wellbeing and high fondness.

Helpful measurement with either 2 mg or 4 mg once day by day was adequate to arrive at the plasma centralization of hindrance [29]. In any case, as we referenced over, the greatest worry about JAK inhibitors is that it can repress an assortment of fiery cytokines including INF-a, which assumes a significant job in controlling infection action. Further clinical preliminaries and itemized examination are justified to affirm their adequacy. Until this point in time, there are some enrolled clinical preliminaries of JAK inhibitor: "Study for security and viability of Jakotinib hydrochloride tablets in the treatment serious and intense compounding patients of novel coronavirus pneumonia (COVID-19)" (ChiCTR2000030170); "Extreme epic coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in blend with mesenchymal undifferentiated cells: a forthcoming, single visually impaired, randomized controlled clinical preliminary" (ChiCTR2000029580).

Chloroquine and hydroxychloroquine

Chloroquine (CQ) is an amine acidotropic type of quinine and hydroxychloroquine (HCQ) contrasts from chloroquine by the nearness of a hydroxyl bunch toward the finish of the side chain: the N-ethyl substituent is β-hydroxylated. For quite a long time, CQ and HCQ are cutting edge prescriptions for the treatment and prophylaxis of jungle fever and are additionally used to treat immune system infections, including rheumatoid joint inflammation (RA) and fundamental lupus erythematosus (SLE).

Past investigations announced that CQ/HCQ have an expansive range of antiviral consequences for an assortment of infections as various as human immunodeficiency infection (HIV) [30], Marburg infection, Zika infection [31], dengue infection [32], Ebola infection [33], and SARS-CoV-1 [34,35] and so on. CQ and HCQ can meddle with the authoritative of viral particles to their cell surface receptor or the pH-subordinate endosome-interceded viral passage of encompassed infections to repress the viral cycle [32]. They can likewise meddle with the post-translational adjustment of viral proteins or disable the best possible development of viral protein by pH balance [36]. Moreover, CQ and HCQ can direct resistant framework by influencing cell flagging and creation of favorable to provocative cytokines.

Despite the fact that CQ or HCQ are every now and again utilized for the treatment of rheumatic illnesses because of its immunomodulatory and mitigating impacts, the advantage in treating COVID-19 might be principally credited to its enemy of viral impacts. As of late, CQ and HCQ have been appeared by a few examinations to lessen the SARS-CoV-2 viral load and abbreviate the span of viremia. Regardless of whether their immunomodulatory impact likewise assumes a job in the treatment of COVID-19 despite everything requires further examination. For coronaviruses, the expected restorative advantages of CQ were outstandingly revealed for SARS-CoV-1. *In vitro*, CQ can forestall SARS-CoV-1 from contaminating the glycosylation of an infection cell surface receptor, ACE2 [30]. An exceptionally ongoing distribution of results indicated that CQ is profoundly viable in the control of COVID-19 contamination *in vitro* [37]. Till now, 15 clinical preliminaries have been led in China to test the viability and wellbeing of CQ or HCQ in the treatment of COVID-19, 8 of which were CQ, 6 were HCQ, and another included both CQ and HCQ [38]. Up until this point, in a clinical preliminary including in excess of 100 patients, the chloroquine phosphate bunch indicated viability in lessening the fuel of pneumonia, improving lung imaging discoveries and expanding negative pace of infection nucleic basic analysis. Given these discoveries, the Guidelines (rendition 6) for treatment of COVID-19 suggests chloroquine phosphate is orally regulated at a portion of 500 mg (300 mg for chloroquine) for grown-ups, multiple times/day (close to 10 days) [39]. "Hydroxychloroquine's remedial impact on new coronavirus (COVID-19)" was enrolled (NO: ChiCTR2000029559). As of February 17, 20 patients have been taken a crack at HCQ and essential treatment gathering. Following 1 - 2 days of HCQ treatment, clinical side effects in all patients improved. Following 5 days of HCQ treatment, 19 patients enhanced lung imaging discoveries. Furthermore, none of the mellow patients had a compounding of ailment in HCQ gathering. As to wellbeing, two of them had antagonistic responses of mellow imprudent and slight cerebral pain, and the unfavorable responses vanished subsequent to altering the routine. The consequences of this clinical preliminary affirmed the transient adequacy of HCQ in the treatment of COVID-19, which can adequately improve lung imaging discoveries, advance an infection negative change, and abbreviate the malady course. In spite of the fact that the quantity of cases in HCQ bunch was generally little, current information can give experiences to clinicians. The viability and security of HCQ in the treatment of COVID-19 should be affirmed in further preclinical and clinical preliminaries.

Conclusion

All in all, COVID-19 is a viral irresistible malady for the most part showed as fever and pneumonia, against viral and respiratory strong treatments are the standard of medicines for extreme cases. As CS happens in basic patients, which prompts ARDS and different

organ harm, and even demise, hostile to irritation treatment might be applied. In any case, given the viral idea of the COVID-19 CS, and considering a generous impairness of host safe framework in extreme cases, it is basic to adjust the hazard and advantage proportion before beginning subterranean insect irritation treatment. Also, an ideal enemy of aggravation treatment started at the correct window time is of significant significance and ought to be custom fitted in singular patient to accomplish the most good impacts.

Declaration of Competing Interest

The author declares that there is no competing interest in this work.

Bibliography

1. R Channappanavar and S Perlman. "Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology". *Seminars in Immunopathology* 39 (2017): 529-539.

2. BG Chousterman., *et al*. "Cytokine storm and sepsis disease pathogenesis". *Seminars in Immunopathology* 39 (2017): 517-528.

3. C Huang., *et al*. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". *Lancet* 395 (2020): 497-506.

4. P Conti., *et al*. "Induction of pro inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies". *Journal of Biological Regulators and Homeostatic Agents* 34 (2020): 327-331.

5. F Zhou., *et al*. "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". *Lancet* (2020).

6. Q Ruan., *et al*. "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China". *Intensive Care Medicine* (2020).

7. N Chen., *et al*. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". *Lancet* 395 (2020): 507-513.

8. C Wu., *et al*. "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease2019 pneumonia in Wuhan, China". *JAMA International Medicine* (2020).

9. S Wan., *et al*. "Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)". *medRxiv* (2020).

10. Z Xu., *et al*. "Pathological findings of COVID-19 associated with acute respiratory distress syndrome". *Lancet Respiratory Medicine* (2020).

11. HK Siddiqi and MR Mehra. "COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal". *Journal of Heart Lung Transplantation* 9.5 (2020): 405-407.

12. National Health Commission of the People's Republic of China. The Diagnosis and Treatment Plan for 2019-nCoV (The Seventh Trial Edition).

13. C Qin., *et al*. "Dysregulation of immune response in patients with COVID-19 in Wuhan, China". *Clinical Infection Disease* (2020).

14. XH Yao., *et al*. "A pathological report of three COVID-19 cases by minimally invasive autopsies". *Chinese Journal of Pathology* 49 (2020): E009.

15. X Guo and P Thomas. "New fronts emerge in the influenza cytokine storm". *Seminars in Immunopathology* 39 (2017): 541-550.

16. A Shimabukuro-Vornhagen., *et al*. "Cytokine release syndrome". *Journal of Immunotherapy Cancer* 6 (2018): 56.

17. C Chen., *et al*. "Advances in the research of cytokine storm mechanism induced by Corona virus disease 2019 and the corresponding immunotherapies". *Chinese Journal of Burns* 36 (2020): E005.

18. TW Auyeung., *et al*. "The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study". *International Journal of Information Security* 51 (2005): 98-102.

19. JC Ho., *et al*. "High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome". *American Journal of Respiratory and Critical Care Medicine* 168 (2003): 1449-1456.

20. LY Yam., *et al*. "Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong". *International Journal of Information Security* 54 (2007): 28-39.

21. RC Chen., *et al*. "Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience". *Chest* 129 (2006): 1441-1452.

22. A Rhodes., *et al*. "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016". *Intensive Care Medicine* 43 (2017): 304-377.

23. P Sun., *et al*. "Understanding of COVID-19 based on current evidence". *Journal of Medical Virology* (2020).

24. KW Chan., *et al*. "COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease". *The American Journal of Chinese Medicine* (2020): 1-26.

25. N Chen., *et al*. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". *Lancet* 395 (2020): 507-513.

26. D Wang., *et al*. "Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China". *JAMA* (2020).

27. CD Russell., *et al*. "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury". *Lancet* 395 (2020): 473-475.

28. World Health Organization, Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected.

29. P Richardson., *et al*. "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease". *Lancet* 395 (2020): e30-e31.

30. J Lajoie., *et al*. "Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention". *AIDS Research Therapy* 14 (2017): 46.

31. A Kumar., *et al*. "Hydroxychloroquine inhibits Zika virus NS2B-NS3 protease". *ACS Omega* 3 (2018): 18132-18141.

32. LF Wang., *et al*. "Hydroxychloroquine inhibited dengue virus is associated with host defense machinery". *Journal of Interferon and Cytokine Research* 35 (2015): 143-156.

33. H Akpovwa. "Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity". *Cell Biochemistry Function* 34 (2016): 191-196.

34. DL Barnard., *et al*. "Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice". *Antiviral Chemistry and Chemotherapy* 17 (2006): 275-284.

35. MJ Vincent., *et al*. "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread". *Virology Journal* 2 (2005): 69.

36. VB Randolph., *et al*. "Acidotropic amines inhibit proteolytic processing of flavivirus prM protein". *Virology* 174.2 (1990): 450-458.

37. M Wang., *et al*. "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". *Cell Research* 30 (2020): 269-271.

38. Q Zhang., *et al*. "Clinical trial analysis of 2019-nCoV therapy registered in China". *Journal of Medical Virology* (2020).

39. L Dong., *et al*. "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". *Drug Discovery Therapy* 14 (2020): 58-60.

Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: https://www.actascientific.com/

Submit Article: https://www.actascientific.com/submission.php

Email us: editor@actascientific.com

Contact us: +91 9182824667